Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Tazverik Generic Name & Formulations
Legal Class
Rx
General Description
Tazemetostat 200mg; tabs.
Pharmacological Class
Methyltransferase inhibitor.
How Supplied
Tabs—240
Manufacturer
Generic Availability
NO
Tazverik Indications
Indications
Metastatic or locally advanced epithelioid sarcoma in patients not eligible for complete resection.
Tazverik Dosage and Administration
Adult
Swallow whole. ≥16yrs: 800mg twice daily; continue until disease progression or unacceptable toxicity. Dose modifications for adverse reactions or for drug interactions: see full labeling.
Children
<16yrs: not established.
Tazverik Contraindications
Not Applicable
Tazverik Boxed Warnings
Not Applicable
Tazverik Warnings/Precautions
Warnings/Precautions
Increased risk of secondary malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, T-cell lymphoblastic lymphoma). Embryo-fetal toxicity. Advise to use effective contraception (non-hormonal) during and for 6 months (females of reproductive potential) and for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).
Tazverik Pharmacokinetics
See Literature
Tazverik Interactions
Interactions
May be potentiated by strong or moderate CYP3A inhibitors; avoid. If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce dose (see full labeling). May be antagonized by strong or moderate CYP3A inducers; avoid. May antagonize CYP3A substrates, including hormonal contraceptives.
Tazverik Adverse Reactions
Adverse Reactions
Pain, fatigue, nausea, decreased appetite, vomiting, constipation, upper RTI, musculoskeletal pain, abdominal pain; lab abnormalities.
Tazverik Clinical Trials
See Literature
Tazverik Note
Not Applicable
Tazverik Patient Counseling
See Literature
Tazverik Generic Name & Formulations
Legal Class
Rx
General Description
Tazemetostat 200mg; tabs.
Pharmacological Class
Methyltransferase inhibitor.
How Supplied
Tabs—240
Manufacturer
Generic Availability
NO
Tazverik Indications
Indications
Relapsed or refractory follicular lymphoma in patients whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, or in patients with no satisfactory alternative treatment options.
Tazverik Dosage and Administration
Adult
Confirm presence of EZH2 mutation of codons Y646, A682, or A692 in tumor specimens. Swallow whole. ≥16yrs: 800mg twice daily; continue until disease progression or unacceptable toxicity. Dose modifications for adverse reactions or for drug interactions: see full labeling.
Children
<16yrs: not established.
Tazverik Contraindications
Not Applicable
Tazverik Boxed Warnings
Not Applicable
Tazverik Warnings/Precautions
Warnings/Precautions
Increased risk of secondary malignancies (eg, myelodysplastic syndrome, acute myeloid leukemia, T-cell lymphoblastic lymphoma). Embryo-fetal toxicity. Advise to use effective contraception (non-hormonal) during and for 6 months (females of reproductive potential) and for 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).
Tazverik Pharmacokinetics
See Literature
Tazverik Interactions
Interactions
May be potentiated by strong or moderate CYP3A inhibitors; avoid. If concomitant use with moderate CYP3A inhibitors is unavoidable, reduce dose (see full labeling). May be antagonized by strong or moderate CYP3A inducers; avoid. May antagonize CYP3A substrates, including hormonal contraceptives.
Tazverik Adverse Reactions
Adverse Reactions
Pain, fatigue, nausea, decreased appetite, vomiting, constipation, upper RTI, musculoskeletal pain, abdominal pain; lab abnormalities.
Tazverik Clinical Trials
See Literature
Tazverik Note
Not Applicable
Tazverik Patient Counseling
See Literature
